Paul Y. Song is CEO at NKGen Biotech, Inc. (NKGN). They have made 5 open-market trades across 1 company since 2023, most recently 2025-05-05.
CIK 0001991119
5 open-market purchases totalling $5.4M since 2023, never a sale. Across 5 scored buys the stock is down 48.9% at ninety days, and 59.7 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NKGN | 21,020,846 | $4.0M |
Shares reported on the most recent Form 4, priced at the 2025-05-07 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 20% | 0% |
| Avg Move | +4.7% | -7.5% | -48.9% |
| Alpha | +2.2% | -11.5% | -59.7% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKGN | BUY | 2025-05-05 | 2025-05-07 | $0.13 | $5.4M | +0.0% | +0.0% | +0.0% |
| NKGN | BUY | 2023-12-06 | 2023-12-07 | $3.31 | $500 | -8.3% | -18.2% | -45.5% |
| NKGN | BUY | 2023-12-04 | 2023-12-05 | $3.18 | $850 | -1.8% | -19.3% | -75.6% |
| NKGN | BUY | 2023-11-27 | 2023-11-28 | $2.88 | $701 | +16.8% | +5.5% | -67.0% |
| NKGN | BUY | 2023-11-21 | 2023-11-22 | $2.83 | $430 | +16.6% | -5.5% | -56.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.